Information updates

Further Update - EpiPen® 300mcg adrenaline (epinephrine) autoinjectors supply delay

23 February 2018:  

Mylan has advised that new stock of EpiPen® 300mcg adrenaline autoinjectors is now due to arrive by Friday 2 March and is expected to be available in pharmacies the following week. This will be followed by further new stock arriving soon afterwards. This has been updated since the previous notice that advised stock would be available by late February 2018. 

To ensure those at risk of anaphylaxis have access to the treatment they may need, supply should be restricted to patients with an EpiPen® prescription for a new diagnosis, or because their EpiPen® has expired or has recently been used.  We thank you in advance for your consideration of others at this challenging time.

We also request that schools and early childhood education and care (ECEC) centres take into account the current supply issues, by not requesting additional devices to be brought to the school or ECEC centre for each child at risk of anaphylaxis, and to limit the replacement of general use devices at this time. 

It is important to note that currently there is no shortage of EpiPen® Jr 150mcg adrenaline autoinjectors. If a pharmacy is out of stock of EpiPen® Jr, the pharmacist should contact their wholesaler/s to obtain stock. If there are any problems they should phone Mylan on 1800 274 276.

A process has been put in place by Mylan to ensure those at risk of anaphylaxis have access to the treatment they may need. Patients requiring an EpiPen® 300mcg autoinjector should go to their local pharmacy.  If that pharmacy does not have stock then the pharmacist should then contact Mylan (phone 1800 274 276 or email This email address is being protected from spambots. You need JavaScript enabled to view it.) to obtain instructions on how to access emergency supply.  

Individuals will be able to access one in-date adrenaline autoinjector until the shortage resolves by early March 2018.  It is important to note that a device expiring in March 2018 does not actually expire until the end of that month, not the start of that month. Patients should retain their recently expired autoinjector/s (see information below).

In the case of anaphylaxis, patients and/or carers should follow instructions on their ASCIA Action Plan (Give EpiPen® and call an ambulance by phoning 000 AU or 111 NZ). 

Patients and/or carers who require support should contact the national patient support organisations, Allergy & Anaphylaxis Australia (phone 1300 728 000 or email This email address is being protected from spambots. You need JavaScript enabled to view it.) or Allergy New Zealand

Use of expired adrenaline autoinjectors

Whilst the use of an expired adrenaline autoinjector is not ideal, research suggests that recently expired devices retain potency. Therefore, if no other adrenaline autoinjector is available, use of a recently expired device to treat anaphylaxis is advised, as stated on the ASCIA website:

Content updated 23 Februay 2018

Mod ASCIA Member
Donate to AIFA
go to NAS website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:


ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.



This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.